Cellular Physiology and Biochemistry (Nov 2014)

Delivery of Placenta-Derived Mesenchymal Stem Cells Ameliorates Ischemia Induced Limb Injury by Immunomodulation

  • Bo Zhang,
  • T.M. Ayodele Adesanya,
  • Li Zhang,
  • Nanzi Xie,
  • Zhishui Chen,
  • Minghuan Fu,
  • Jie Zhang,
  • Jian Zhang,
  • Tao Tan,
  • Ahmet Kilic,
  • Zhihong Li,
  • Hua Zhu,
  • Xiaoyun Xie

DOI
https://doi.org/10.1159/000366395
Journal volume & issue
Vol. 34, no. 6
pp. 1998 – 2006

Abstract

Read online

Background: Peripheral artery disease (PAD) is a major health burden in the world. Stem cell-based therapy has emerged as an attractive treatment option in regenerative medicine. In this study, we sought to test the hypothesis that stem cell-based therapy can ameliorate ischemia induced limb injury. Methods: We isolated mesenchymal stem cells derived from human placentas (PMSCs) and intramuscularly transplanted them into injured hind limbs. Treatment with PMSCs reduced acute muscle fibers apoptosis induced by ischemia. Results: PMSC treatment significantly enhanced regeneration of the injured hind limb by reducing fibrosis and enhancing running capacity when the animals were subjected to treadmill training. Mechanistically, injected PMSCs can modulate acute inflammatory responses by reducing neutrophil and macrophage infiltration following limb ischemia. ELISA assays further confirmed that PMSC treatment can also reduce pro-inflammatory cytokines, TNF-α and IL-6, and enhance anti-inflammatory cytokine, IL-10 at the injury sites. Conclusion: Taken together, our results demonstrated that PMSCs can be a potential effective therapy for treatment of PAD via immunomodulation.

Keywords